Latest News - Thermo Fisher Scientific
Top Corporates Hub
Thermo Fisher Scientific
What Sent Illumina Stock Lower?
02.11.2026 01:23
For questions about this article or underlying research, email help@trefis.com.
Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q3 Beat And Higher Guidance
31.10.2026 20:07
The fair value estimate for Thermo Fisher Scientific has shifted from US$686.64 to US$750.92, giving investors an updated anchor for thinking about the stock. This change sits within a wider mix of bullish and cautious analyst views that lean on Q3 2026 results, guidance and the debate around long term growth targets. As you read on, you will see how this evolving narrative fits together and how to keep track of future updates. Stay updated as the Fair Value for Thermo Fisher Scientific...
How Investors Are Reacting To Thermo Fisher Scientific Stock After Strong Q3 Earnings
31.10.2026 05:10
Thermo Fisher Scientific reported past third quarter 2026 results with sales of US$12.137b and net income of US$1.721b, with earnings per share from continuing operations modestly higher than a year earlier on both a basic and diluted basis. Beyond near term figures, Thermo Fisher Scientific is tied to fast growing areas like synthetic gene circuits, viral genome sequencing, and population genomic screening. This points to meaningful exposure to AI enabled precision medicine and advanced...
Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGEN
30.10.2026 15:20
Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global human papillomavirus (HPV) genotyping panels market is demonstrating steady growth as healthcare systems expand cervical cancer screening, strengthen molecular diagnostic capabilities, and increase their focus on the early detection of HPV-related cancers. The market is projected to grow from $1.79 billion in 2025 to $1
Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AI
30.10.2026 15:19
Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clinical Genomics Interpretation Platforms Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global clinical genomics interpretation platforms market is experiencing rapid growth, supported by increased use of next-generation sequencing, expanding genomic research initiatives and rising demand for personalized healthcare. The market is projected to grow from $1.52 billion in 2025 to $1.74 billion in 2026, representing a
Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche
30.10.2026 14:42
Profiles Roche Diagnostics, Thermo Fisher Scientific, Merck KGaA, Agilent Technologies and Silence Therapeutics, covering their RNAi technology market activities.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Ribonucleic Acid (RNA) Interference Technology Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global ribonucleic acid (RNA) interference technology market is experiencing rapid growth as pharmaceutical and biotechnology companies expand the development of RN
Clinical Genomics Sequencing, Biobank, and Database Services Global Market to 2035 | Capitalize on AI and Precision Medicine: Illumina, Thermo Fisher, BGI Genomics, Tempus AI
30.10.2026 14:34
Boost ROI by scaling commercial services, integrating AI and secure cloud genomics, forming data partnerships, expanding into emerging markets, and using tiered pricing and account-based marketing.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clinical Genomics Sequencing, Biobank, Database Services Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The global clinical genomics sequencing, biobank and database services market reached approximatel
Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and Illumina
30.10.2026 14:27
Players: Thermo Fisher, Labcorp, Quest Diagnostics, Eurofins, Agilent. Profiles cover fetal aneuploidy tests, technologies, applications and end users.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Fetal Aneuploidy Confirmation Testing Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global fetal aneuploidy confirmation testing market is experiencing rapid expansion as healthcare systems increase their focus on accurate prenatal diagnosis and advanced genetic analy
Global Gene Panel Reconciliation Services Market Report 2026 | Capitalize on AI-Driven Genomics as Roche, Thermo Fisher, Illumina and QIAGEN Accelerate a $2.38B Market by 2030
30.10.2026 14:26
Players: Roche, Thermo Fisher, IQVIA, Labcorp, Eurofins. Profiled: gene-panel design, harmonization, interpretation, reporting, technologies, applications and regions.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Gene Panel Reconciliation Services Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global gene panel reconciliation services market is experiencing rapid growth, supported by expanding clinical genetic testing, increased use of next-generation sequencing
Illumina Sinks 13% on Light Q3 Revenue Despite EPS Beat and Raised Guidance
30.10.2026 14:01
Key TakeawaysIllumina shares fell 13% after third-quarter revenue of $1. 13 billion missed consensus, even though adjusted EPS beat and full-year guidance went up.
2 cash-producing stocks with promising prospects and 1 we avoid
30.10.2026 13:31
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
30.10.2026 10:28
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?
30.10.2026 09:57
IDEXX Laboratories (NASDAQ:IDXX) is scheduled to report its earnings on Monday, November 2, 2026. The company has a market value of about $45.5 billion. Over the last twelve months it generated $4.6 billion in revenue and $1.5 billion in operating profit, with net income of $1.1 billion.
Is Thermo Fisher Scientific (TMO) Fully Priced On Its Latest Results?
29.10.2026 04:31
Thermo Fisher Scientific (TMO) released third quarter 2026 results that showed sales of US$12.1b and net income of US$1.7b. These figures frame how the stock’s recent move might be interpreted. Thermo Fisher Scientific shares have been building momentum, with a 22.1% 90 day share price return and 18.8% year to date, alongside a 26.6% one year total shareholder return that points to investors becoming more comfortable with the risk and earnings profile. Scan beyond Thermo Fisher Scientific and...
Thermo Fisher (TMO) Stock Could Trade At A Premium On Strong Q3 Results
29.10.2026 03:09
Thermo Fisher Scientific has delivered a strong share-price run in recent years, and that kind of climb naturally raises a question for you as an investor. Is the current US$704.15 price still in line with what the business can generate in cash over time, or has sentiment moved ahead of those cash flows? The stock has returned 61.2% over the past 3 years, which puts real weight on whether that gain is backed up by the durability and scale of future cash generation. Recent product launches in...
Microarray Scanners - Global Strategic Business Report 2026: Capitalize on $1.6 Billion Industry Revenue by 2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina, and Bio-Rad Laboratories Dominate
28.10.2026 16:00
Dublin, Oct. 28, 2026 (GLOBE NEWSWIRE) -- "Microarray Scanners - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global microarray scanners market was valued at US$986.1 million in 2025 and is projected to reach US$1.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.2%. Market expansion is being supported by growing investment in genomics, precision medicine, molecular diagnostics, pharmaceutical research and high-throughput biol
Breakout Watch: 4 Reasons To Monitor This Top-Rated Medical Stock
28.10.2026 11:30
A best-possible 99 Composite Rating is just one reason to watch Medpace stock. Here are four more telltale clues to monitor.
Global DNA Sequencing in Drug Discovery Market Report 2026 | Capitalize on 12.5% CAGR as Illumina, Thermo Fisher, QIAGEN, and Oxford Nanopore Accelerate AI-Driven Precision R&D
26.10.2026 14:36
Boost ROI through lower-cost assays, AI-driven analysis, local consumables production, supplier diversification, multiomics, and pharma-biotech partnerships.Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Deoxyribonucleic Acid (DNA) Sequencing in Drug Discovery Market Report 2026" has been added to ResearchAndMarkets.com's offering. DNA Sequencing in Drug Discovery Market to Reach $15.22 Billion by 2030 as Precision Medicine Advances The global deoxyribonucleic acid (DNA) sequencing in drug discovery
Cell and Gene Therapy Contract Research Organization Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec Scale Integrated Trials
26.10.2026 14:32
Boost ROI by outsourcing R&D, integrating preclinical and clinical services, leveraging data-driven trials, strengthening compliance, and localizing labs to reduce tariff costs.Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Cell and Gene Therapy Contract Research Organization Market Report 2026" has been added to ResearchAndMarkets.com's offering. Cell and Gene Therapy Contract Research Organization Market to Reach $12.36 Billion by 2030 The global cell and gene therapy contract research organizatio
Qiagen agrees to private equity takeover
23.10.2026 13:00
EQT Private Equity has agreed to pay about $12.1 billion, including debt, for the diagnostics company, which has long been the subject of takeover speculation.